Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 30 entries
Sorted by: Best Match Show Resources per page
Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.

Infection & chemotherapy

Lal A, Jaoude P, El-Solh AA.
PMID: 27433378
Infect Chemother. 2016 Jun;48(2):81-90. doi: 10.3947/ic.2016.48.2.81. Epub 2016 Jun 30.

BACKGROUND: The primary objective of this meta-analysis is aimed at determining whether β-lactams prolonged infusion in patients with nosocomial pneumonia (NP) results in higher cure rate and improved mortality compared to intermittent infusion.MATERIALS AND METHODS: Relevant studies were identified...

Cite
Lal A, Jaoude P, El-Solh AA. Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother. 2016;48(2):81-90doi: 10.3947/ic.2016.48.2.81.
Lal, A., Jaoude, P., & El-Solh, A. A. (2016). Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infection & chemotherapy, 48(2), 81-90. https://doi.org/10.3947/ic.2016.48.2.81
Lal, Ashima, et al. "Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis." Infection & chemotherapy vol. 48,2 (2016): 81-90. doi: https://doi.org/10.3947/ic.2016.48.2.81
Lal A, Jaoude P, El-Solh AA. Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother. 2016 Jun;48(2):81-90. doi: 10.3947/ic.2016.48.2.81. Epub 2016 Jun 30. PMID: 27433378; PMCID: PMC4945731.
Copy Download .nbib Format: NLM
Glioblastoma and Increased Survival with Longer Chemotherapy Duration.

Kansas journal of medicine

Jaoude DA, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF.
PMID: 31489102
Kans J Med. 2019 Aug 21;12(3):65-69. eCollection 2019 Aug.

INTRODUCTION: The five-year survival rate for patients with glioblastoma (GBM) is low at approximately 4.7%. Radiotherapy plus concomitant and adjuvant temozolomide (TMZ) remains the standard of care. The optimal duration of therapy with TMZ is unknown. This study sought...

Cite
Jaoude DA, Moore JA, Moore MB, et al. Glioblastoma and Increased Survival with Longer Chemotherapy Duration. Kans J Med. 2019;12(3):65-69
Jaoude, D. A., Moore, J. A., Moore, M. B., Twumasi-Ankrah, P., Ablah, E., & Moore, D. F. (2019). Glioblastoma and Increased Survival with Longer Chemotherapy Duration. Kansas journal of medicine, 12(3), 65-69.
Jaoude, Dory Abou, et al. "Glioblastoma and Increased Survival with Longer Chemotherapy Duration." Kansas journal of medicine vol. 12,3 (2019): 65-69.
Jaoude DA, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF. Glioblastoma and Increased Survival with Longer Chemotherapy Duration. Kans J Med. 2019 Aug 21;12(3):65-69. eCollection 2019 Aug. PMID: 31489102; PMCID: PMC6710024.
Copy Download .nbib Format: NLM
The radiotherapy quality assurance gap among phase III cancer clinical trials.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB.
PMID: 34838891
Radiother Oncol. 2021 Nov 25;166:51-57. doi: 10.1016/j.radonc.2021.11.018. Epub 2021 Nov 25.

PURPOSE: Quality assurance (QA) practices improve the quality level of oncology trials by ensuring that the protocol is followed and the results are valid and reproducible. This study investigated the utilization of QA among randomized controlled trials that involve...

Cite
Corrigan KL, Kry S, Howell RM, et al. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2021;166:51-57doi: 10.1016/j.radonc.2021.11.018.
Corrigan, K. L., Kry, S., Howell, R. M., Kouzy, R., Jaoude, J. A., Patel, R. R., Jhingran, A., Taniguchi, C., Koong, A. C., McAleer, M. F., Nitsch, P., Rödel, C., Fokas, E., Minsky, B. D., Das, P., Fuller, C. D., & Ludmir, E. B. (2021). The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16651-57. https://doi.org/10.1016/j.radonc.2021.11.018
Corrigan, Kelsey L, et al. "The radiotherapy quality assurance gap among phase III cancer clinical trials." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 166 (2021): 51-57. doi: https://doi.org/10.1016/j.radonc.2021.11.018
Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2021 Nov 25;166:51-57. doi: 10.1016/j.radonc.2021.11.018. Epub 2021 Nov 25. PMID: 34838891.
Copy Download .nbib Format: NLM
Post-lumpectomy radiation therapy boost in breast cancer patients: evidence revisited.

Ecancermedicalscience

Kayali M, Jaoude JA, Ramia P, Assi H, Geara F, Poortmans P, Zeidan YH.
PMID: 33889203
Ecancermedicalscience. 2021 Mar 01;15:1194. doi: 10.3332/ecancer.2021.1194. eCollection 2021.

PURPOSE: Radiation therapy is an integral part in the management of breast cancer after breast conservative surgery. In selected patients at high risk for local recurrence (LR), a boost radiation dose is commonly applied to the tumour bed.METHODS: We...

Cite
Kayali M, Jaoude JA, Ramia P, et al. Post-lumpectomy radiation therapy boost in breast cancer patients: evidence revisited. Ecancermedicalscience. 2021;15:1194doi: 10.3332/ecancer.2021.1194.
Kayali, M., Jaoude, J. A., Ramia, P., Assi, H., Geara, F., Poortmans, P., & Zeidan, Y. H. (2021). Post-lumpectomy radiation therapy boost in breast cancer patients: evidence revisited. Ecancermedicalscience, 151194. https://doi.org/10.3332/ecancer.2021.1194
Kayali, Majd, et al. "Post-lumpectomy radiation therapy boost in breast cancer patients: evidence revisited." Ecancermedicalscience vol. 15 (2021): 1194. doi: https://doi.org/10.3332/ecancer.2021.1194
Kayali M, Jaoude JA, Ramia P, Assi H, Geara F, Poortmans P, Zeidan YH. Post-lumpectomy radiation therapy boost in breast cancer patients: evidence revisited. Ecancermedicalscience. 2021 Mar 01;15:1194. doi: 10.3332/ecancer.2021.1194. eCollection 2021. PMID: 33889203; PMCID: PMC8043677.
Copy Download .nbib Format: NLM
Two new triterpenoid fatty acid esters from .

Natural product research

Mbougnia JFT, Bitchagno GTM, Wouamba SCN, Jouda JB, Awouafack MD, Tene M, Lenta BN, Kouam SF, Tane P, Sewald N.
PMID: 33203260
Nat Prod Res. 2020 Nov 18;1-12. doi: 10.1080/14786419.2020.1849199. Epub 2020 Nov 18.

Two new fatty acid esters of triterpenoids (

Cite
Mbougnia JFT, Bitchagno GTM, Wouamba SCN, et al. Two new triterpenoid fatty acid esters from . Nat Prod Res. 2020;1-12doi: 10.1080/14786419.2020.1849199.
Mbougnia, J. F. T., Bitchagno, G. T. M., Wouamba, S. C. N., Jouda, J. B., Awouafack, M. D., Tene, M., Lenta, B. N., Kouam, S. F., Tane, P., & Sewald, N. (2020). Two new triterpenoid fatty acid esters from . Natural product research, 1-12. https://doi.org/10.1080/14786419.2020.1849199
Mbougnia, Judith Flore T, et al. "Two new triterpenoid fatty acid esters from ." Natural product research vol. (2020): 1-12. doi: https://doi.org/10.1080/14786419.2020.1849199
Mbougnia JFT, Bitchagno GTM, Wouamba SCN, Jouda JB, Awouafack MD, Tene M, Lenta BN, Kouam SF, Tane P, Sewald N. Two new triterpenoid fatty acid esters from . Nat Prod Res. 2020 Nov 18;1-12. doi: 10.1080/14786419.2020.1849199. Epub 2020 Nov 18. PMID: 33203260.
Copy Download .nbib Format: NLM
High-Flux, Antifouling Hydrophilized Ultrafiltration Membranes with Tunable Charge Density Combining Sulfonated Poly(ether sulfone) and Aminated Graphene Oxide Nanohybrid.

ACS applied materials & interfaces

Kumar M, Sreedhar N, Jaoude MA, Arafat HA.
PMID: 31834764
ACS Appl Mater Interfaces. 2020 Jan 08;12(1):1617-1627. doi: 10.1021/acsami.9b19387. Epub 2019 Dec 20.

In this work, a new protocol was developed for creating charge-tuned, hydrophilic hybrid ultrafiltration (UF) membranes with high flux, rejection rate, and fouling resistance. The membranes were fabricated using a combination of sulfonated poly(ether sulfone) (SPES) and aminated graphene...

Cite
Kumar M, Sreedhar N, Jaoude MA, et al. High-Flux, Antifouling Hydrophilized Ultrafiltration Membranes with Tunable Charge Density Combining Sulfonated Poly(ether sulfone) and Aminated Graphene Oxide Nanohybrid. ACS Appl Mater Interfaces. 2019;12(1):1617-1627doi: 10.1021/acsami.9b19387.
Kumar, M., Sreedhar, N., Jaoude, M. A., & Arafat, H. A. (2020). High-Flux, Antifouling Hydrophilized Ultrafiltration Membranes with Tunable Charge Density Combining Sulfonated Poly(ether sulfone) and Aminated Graphene Oxide Nanohybrid. ACS applied materials & interfaces, 12(1), 1617-1627. https://doi.org/10.1021/acsami.9b19387
Kumar, Mahendra, et al. "High-Flux, Antifouling Hydrophilized Ultrafiltration Membranes with Tunable Charge Density Combining Sulfonated Poly(ether sulfone) and Aminated Graphene Oxide Nanohybrid." ACS applied materials & interfaces vol. 12,1 (2020): 1617-1627. doi: https://doi.org/10.1021/acsami.9b19387
Kumar M, Sreedhar N, Jaoude MA, Arafat HA. High-Flux, Antifouling Hydrophilized Ultrafiltration Membranes with Tunable Charge Density Combining Sulfonated Poly(ether sulfone) and Aminated Graphene Oxide Nanohybrid. ACS Appl Mater Interfaces. 2020 Jan 08;12(1):1617-1627. doi: 10.1021/acsami.9b19387. Epub 2019 Dec 20. PMID: 31834764.
Copy Download .nbib Format: NLM
The radiotherapy quality assurance gap among phase III cancer clinical trials.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB.
PMID: 34838891
Radiother Oncol. 2021 Nov 25;166:51-57. doi: 10.1016/j.radonc.2021.11.018. Epub 2021 Nov 25.

PURPOSE: Quality assurance (QA) practices improve the quality level of oncology trials by ensuring that the protocol is followed and the results are valid and reproducible. This study investigated the utilization of QA among randomized controlled trials that involve...

Cite
Corrigan KL, Kry S, Howell RM, et al. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2021;166:51-57doi: 10.1016/j.radonc.2021.11.018.
Corrigan, K. L., Kry, S., Howell, R. M., Kouzy, R., Jaoude, J. A., Patel, R. R., Jhingran, A., Taniguchi, C., Koong, A. C., McAleer, M. F., Nitsch, P., Rödel, C., Fokas, E., Minsky, B. D., Das, P., Fuller, C. D., & Ludmir, E. B. (2021). The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16651-57. https://doi.org/10.1016/j.radonc.2021.11.018
Corrigan, Kelsey L, et al. "The radiotherapy quality assurance gap among phase III cancer clinical trials." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 166 (2021): 51-57. doi: https://doi.org/10.1016/j.radonc.2021.11.018
Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2021 Nov 25;166:51-57. doi: 10.1016/j.radonc.2021.11.018. Epub 2021 Nov 25. PMID: 34838891.
Copy Download .nbib Format: NLM
The radiotherapy quality assurance gap among phase III cancer clinical trials.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB.
PMID: 34838891
Radiother Oncol. 2021 Nov 25;166:51-57. doi: 10.1016/j.radonc.2021.11.018. Epub 2021 Nov 25.

PURPOSE: Quality assurance (QA) practices improve the quality level of oncology trials by ensuring that the protocol is followed and the results are valid and reproducible. This study investigated the utilization of QA among randomized controlled trials that involve...

Cite
Corrigan KL, Kry S, Howell RM, et al. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2021;166:51-57doi: 10.1016/j.radonc.2021.11.018.
Corrigan, K. L., Kry, S., Howell, R. M., Kouzy, R., Jaoude, J. A., Patel, R. R., Jhingran, A., Taniguchi, C., Koong, A. C., McAleer, M. F., Nitsch, P., Rödel, C., Fokas, E., Minsky, B. D., Das, P., Fuller, C. D., & Ludmir, E. B. (2021). The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16651-57. https://doi.org/10.1016/j.radonc.2021.11.018
Corrigan, Kelsey L, et al. "The radiotherapy quality assurance gap among phase III cancer clinical trials." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 166 (2021): 51-57. doi: https://doi.org/10.1016/j.radonc.2021.11.018
Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2021 Nov 25;166:51-57. doi: 10.1016/j.radonc.2021.11.018. Epub 2021 Nov 25. PMID: 34838891.
Copy Download .nbib Format: NLM
The radiotherapy quality assurance gap among phase III cancer clinical trials.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB.
PMID: 34838891
Radiother Oncol. 2021 Nov 25;166:51-57. doi: 10.1016/j.radonc.2021.11.018. Epub 2021 Nov 25.

PURPOSE: Quality assurance (QA) practices improve the quality level of oncology trials by ensuring that the protocol is followed and the results are valid and reproducible. This study investigated the utilization of QA among randomized controlled trials that involve...

Cite
Corrigan KL, Kry S, Howell RM, et al. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2021;166:51-57doi: 10.1016/j.radonc.2021.11.018.
Corrigan, K. L., Kry, S., Howell, R. M., Kouzy, R., Jaoude, J. A., Patel, R. R., Jhingran, A., Taniguchi, C., Koong, A. C., McAleer, M. F., Nitsch, P., Rödel, C., Fokas, E., Minsky, B. D., Das, P., Fuller, C. D., & Ludmir, E. B. (2021). The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16651-57. https://doi.org/10.1016/j.radonc.2021.11.018
Corrigan, Kelsey L, et al. "The radiotherapy quality assurance gap among phase III cancer clinical trials." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 166 (2021): 51-57. doi: https://doi.org/10.1016/j.radonc.2021.11.018
Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol. 2021 Nov 25;166:51-57. doi: 10.1016/j.radonc.2021.11.018. Epub 2021 Nov 25. PMID: 34838891.
Copy Download .nbib Format: NLM
Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease.

European heart journal. Cardiovascular pharmacotherapy

Franchi F, Rollini F, Been L, Maaliki N, Jaoude PA, Rivas A, Zhou X, Jia S, Briceno M, Lee CH, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ.
PMID: 34114623
Eur Heart J Cardiovasc Pharmacother. 2021 Jun 11; doi: 10.1093/ehjcvp/pvab042. Epub 2021 Jun 11.

AIMS: Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Ticagrelor reduces ischaemic events compared to clopidogrel, with the greatest risk reduction in patients with both DM and CKD. How CKD...

Cite
Franchi F, Rollini F, Been L, et al. Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. Eur Heart J Cardiovasc Pharmacother. 2021;doi: 10.1093/ehjcvp/pvab042.
Franchi, F., Rollini, F., Been, L., Maaliki, N., Jaoude, P. A., Rivas, A., Zhou, X., Jia, S., Briceno, M., Lee, C. H., Pineda, A. M., Suryadevara, S., Soffer, D., Zenni, M. M., Bass, T. A., & Angiolillo, D. J. (2021). Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. European heart journal. Cardiovascular pharmacotherapy, . https://doi.org/10.1093/ehjcvp/pvab042
Franchi, Francesco, et al. "Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease." European heart journal. Cardiovascular pharmacotherapy vol. (2021). doi: https://doi.org/10.1093/ehjcvp/pvab042
Franchi F, Rollini F, Been L, Maaliki N, Jaoude PA, Rivas A, Zhou X, Jia S, Briceno M, Lee CH, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ. Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. Eur Heart J Cardiovasc Pharmacother. 2021 Jun 11; doi: 10.1093/ehjcvp/pvab042. Epub 2021 Jun 11. PMID: 34114623.
Copy Download .nbib Format: NLM
EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal.

Endoscopic ultrasound

Carrara S, Rimbas M, Larghi A, Di Leo M, Comito T, Jaoude JA, Taniguchi CM, Dietrich CF, Bhutani MS, Hollerbach S.
PMID: 33666180
Endosc Ultrasound. 2021 Mar 02; doi: 10.4103/EUS-D-20-00116. Epub 2021 Mar 02.

We present here a new chapter of the series of papers on how to perform specific EUS techniques. In this manuscript, we discuss on how to perform EUS-guided placement of fiducial markers in gastrointestinal tumors. The aim is to...

Cite
Carrara S, Rimbas M, Larghi A, et al. EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal. Endosc Ultrasound. 2021;doi: 10.4103/EUS-D-20-00116.
Carrara, S., Rimbas, M., Larghi, A., Di Leo, M., Comito, T., Jaoude, J. A., Taniguchi, C. M., Dietrich, C. F., Bhutani, M. S., & Hollerbach, S. (2021). EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal. Endoscopic ultrasound, . https://doi.org/10.4103/EUS-D-20-00116
Carrara, Silvia, et al. "EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal." Endoscopic ultrasound vol. (2021). doi: https://doi.org/10.4103/EUS-D-20-00116
Carrara S, Rimbas M, Larghi A, Di Leo M, Comito T, Jaoude JA, Taniguchi CM, Dietrich CF, Bhutani MS, Hollerbach S. EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal. Endosc Ultrasound. 2021 Mar 02; doi: 10.4103/EUS-D-20-00116. Epub 2021 Mar 02. PMID: 33666180.
Copy Download .nbib Format: NLM
Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumab.

International journal of radiation oncology, biology, physics

Bachir B, Anouti S, Jaoude JA, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan Y.
PMID: 34986381
Int J Radiat Oncol Biol Phys. 2022 Jan 02; doi: 10.1016/j.ijrobp.2021.12.159. Epub 2022 Jan 02.

PURPOSE/OBJECTIVE: Trastuzumab is associated with cardiac dysfunction in patients with HER-2 positive breast cancer. The current study examines the effect of radiation therapy (RT) on cardiotoxicity in this patient population. Materials/ Methods: The HERA trial is a phase III...

Cite
Bachir B, Anouti S, Jaoude JA, et al. Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumab. Int J Radiat Oncol Biol Phys. 2022;doi: 10.1016/j.ijrobp.2021.12.159.
Bachir, B., Anouti, S., Jaoude, J. A., Kayali, M., Tfayli, A., de Azambuja, E., Poortmans, P., & Zeidan, Y. (2022). Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumab. International journal of radiation oncology, biology, physics, . https://doi.org/10.1016/j.ijrobp.2021.12.159
Bachir, B, et al. "Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumab." International journal of radiation oncology, biology, physics vol. (2022). doi: https://doi.org/10.1016/j.ijrobp.2021.12.159
Bachir B, Anouti S, Jaoude JA, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan Y. Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumab. Int J Radiat Oncol Biol Phys. 2022 Jan 02; doi: 10.1016/j.ijrobp.2021.12.159. Epub 2022 Jan 02. PMID: 34986381.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 30 entries